Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
Department of Pharmaceutical Services, Winship Cancer Institute, Emory University Hospitals, Atlanta, Georgia.
Clin Adv Hematol Oncol. 2021 Mar;19(3):166-174.
Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and anti-SLAMF7 monoclonal antibodies were the first to enter the MM portfolio as treatment options for relapsed/ refractory MM. More recently, daratumumab has become important in the treatment of newly diagnosed MM, and a subcutaneous formulation has been approved. BCMA-targeted antibody-drug conjugates and bispecific antibodies, which are the newest antibody therapies to be investigated, provide additional therapeutic options for patients with heavily pretreated MM. This article reviews how antibody therapy has influenced the treatment of MM, describes the unique adverse event profiles of each relevant drug class, and explains how to incorporate antibody therapy into practice.
抗体疗法已成为多发性骨髓瘤（MM）治疗的重要选择，包括单克隆抗体、抗体药物偶联物和双特异性抗体。抗 CD38 和抗 SLAMF7 单克隆抗体是首批作为复发性/难治性 MM 治疗选择进入 MM 治疗方案的药物。最近，达雷妥尤单抗在新诊断 MM 的治疗中变得重要，且已批准皮下制剂。针对 BCMA 的抗体药物偶联物和双特异性抗体是最新研究的抗体疗法，为接受过多线治疗的 MM 患者提供了更多的治疗选择。本文综述了抗体疗法如何影响 MM 的治疗，描述了每个相关药物类别的独特不良事件谱，并解释了如何将抗体疗法纳入临床实践。
